Lifecore Biomedical, Inc. (LFCR) Q1 2026 Earnings Call Transcript
Lifecore Biomedical, Inc. ( LFCR ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Paul Josephs - President, CEO & Director Ryan Lake - Executive VP & CFO Conference Call Participants Stephanie Diaz - Vida Strategic Partners, Inc. Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Hannah Hefley - Stephens Inc., Research Division Lucas Baranowski - KeyBanc Capital Markets Inc., Research Division Christine Rains - William Blair & Company L.L.C., Research Division Presentation Stephanie Diaz Vida Strategic Partners, Inc. Good afternoon, and thank you for joining us today to discuss Lifecore Biomedical's Third Quarter 2025 Earnings results for the 3 months ended September 30, 2025.
Universal Electronics Inc. (UEIC) Q4 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Paul Josephs - President, CEO & Director Ryan D. Lake - EVP & CFO Conference Call Participants Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Maxwell Andrew Smock - William Blair & Company L.L.C.
| Specialty Retail Industry | Consumer Discretionary Sector | Paul Josephs CEO | NASDAQ (NGS) Exchange | 514766104 CUSIP |
| US Country | 524 Employees | - Last Dividend | - Last Split | 15 Feb 1996 IPO Date |
Lifecore Biomedical, Inc., together with its subsidiaries, is renowned for being an integrated contract development and manufacturing organization with a broad international and domestic reach. Previously known as Landec Corporation until its rebranding in November 2022, Lifecore Biomedical has carved a niche for itself in the pharmaceutical industry since its inception in 1965. Based in Chaska, Minnesota, this organization has established itself as a crucial player in the production of pharmaceutical-grade sodium hyaluronate (HA), catering to a variety of medical conditions and procedures throughout the United States and beyond.
Lifecore Biomedical, Inc. offers an extensive array of products and services designed to meet the diverse needs of the healthcare industry, focusing particularly on sodium hyaluronate (HA) based solutions: